CL2008003475A1 - Composiciones farmacéuticas que comprenden una mezcla de a) ácido hialurónico o sus sales de sodio o potasio y b) un antagonista del receptor de bradiquinina b2, útil para la profilaxis y el tratamiento de enfermedades articulares inflamatorias, autoinmunes, traumáticas y degenerativas tales como osteoartritis y bursitis. - Google Patents
Composiciones farmacéuticas que comprenden una mezcla de a) ácido hialurónico o sus sales de sodio o potasio y b) un antagonista del receptor de bradiquinina b2, útil para la profilaxis y el tratamiento de enfermedades articulares inflamatorias, autoinmunes, traumáticas y degenerativas tales como osteoartritis y bursitis.Info
- Publication number
- CL2008003475A1 CL2008003475A1 CL2008003475A CL2008003475A CL2008003475A1 CL 2008003475 A1 CL2008003475 A1 CL 2008003475A1 CL 2008003475 A CL2008003475 A CL 2008003475A CL 2008003475 A CL2008003475 A CL 2008003475A CL 2008003475 A1 CL2008003475 A1 CL 2008003475A1
- Authority
- CL
- Chile
- Prior art keywords
- inflammatory
- osteoarthritis
- traumatic
- autoimmune
- sodium
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000008482 osteoarthritis Diseases 0.000 title abstract 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 2
- 230000001363 autoimmune Effects 0.000 title abstract 2
- 229920002674 hyaluronan Polymers 0.000 title abstract 2
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 159000000001 potassium salts Chemical class 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- 230000000472 traumatic effect Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 229940123765 Bradykinin B2 receptor antagonist Drugs 0.000 title 1
- 206010006811 Bursitis Diseases 0.000 title 1
- 239000003359 bradykinin B2 receptor antagonist Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 206010058314 Dysplasia Diseases 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 208000005801 spondylosis Diseases 0.000 abstract 1
- 201000004595 synovitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN, COMO INGREDIENTES ACTIVOS, UNA MEZCLA DE UN POLÍMERO<br /> DE ÁCIDO HIALURÓNICO O SUS SALES DE SODIO Y POTASIO, CON UN ANTAGONISTA DEL RECEPTOR DE BRADIQUININA B2. SE<br /> REIVINDICA EL USO DE DICHAS COMPOSICIONES EN EL TRATAMIENTO DE ENFERMEDADES ARTICULARES INFLAMATORIAS,<br /> AUTOINMUNES, TRAUMÁTICAS Y DEGENERATIVAS TALES COMO OSTEOARTRITIS ESPONDILOSIS, SINOVITIS, TENOSINOVITIS, BURSITIS, CONTUSIONES, ESGUINCES, LUXACIONES Y SUBLUXACIONES, Y EN ENFERMEDADES ARTICULARES CAUSADAS POR ALTERACIONES DE DESARROLLO TALES COMO OSTEOCONDRITIS Y DISPLASIA.<br />
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002225A ITMI20072225A1 (it) | 2007-11-23 | 2007-11-23 | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008003475A1 true CL2008003475A1 (es) | 2009-03-27 |
Family
ID=40314753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008003475A CL2008003475A1 (es) | 2007-11-23 | 2008-11-21 | Composiciones farmacéuticas que comprenden una mezcla de a) ácido hialurónico o sus sales de sodio o potasio y b) un antagonista del receptor de bradiquinina b2, útil para la profilaxis y el tratamiento de enfermedades articulares inflamatorias, autoinmunes, traumáticas y degenerativas tales como osteoartritis y bursitis. |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9101627B2 (es) |
| EP (1) | EP2222275B1 (es) |
| JP (1) | JP5383695B2 (es) |
| KR (1) | KR101585868B1 (es) |
| CN (1) | CN101868225B (es) |
| AP (1) | AP2628A (es) |
| AR (1) | AR069407A1 (es) |
| AT (1) | ATE529096T1 (es) |
| AU (1) | AU2008328311B2 (es) |
| BR (1) | BRPI0820402A2 (es) |
| CA (1) | CA2706398C (es) |
| CL (1) | CL2008003475A1 (es) |
| CO (1) | CO6270301A2 (es) |
| CR (1) | CR11457A (es) |
| CY (1) | CY1112134T1 (es) |
| DK (1) | DK2222275T3 (es) |
| EA (1) | EA017626B1 (es) |
| EC (1) | ECSP10010153A (es) |
| ES (1) | ES2374861T3 (es) |
| GE (1) | GEP20125602B (es) |
| HN (1) | HN2010001037A (es) |
| HR (1) | HRP20110904T1 (es) |
| IL (1) | IL205860A (es) |
| IT (1) | ITMI20072225A1 (es) |
| MA (1) | MA31913B1 (es) |
| MX (1) | MX2010005484A (es) |
| MY (1) | MY148685A (es) |
| NI (1) | NI201000087A (es) |
| NZ (1) | NZ585514A (es) |
| PA (1) | PA8804801A1 (es) |
| PE (1) | PE20091422A1 (es) |
| PL (1) | PL2222275T3 (es) |
| PT (1) | PT2222275E (es) |
| RS (1) | RS52045B (es) |
| SI (1) | SI2222275T1 (es) |
| TN (1) | TN2010000215A1 (es) |
| TW (1) | TWI448292B (es) |
| UA (1) | UA97867C2 (es) |
| WO (1) | WO2009065507A2 (es) |
| ZA (1) | ZA201003586B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL420378A1 (pl) * | 2014-05-30 | 2017-10-23 | Nataliia Mykolaivna Derkach | Stabilizowany roztwór na bazie substancji czynnych, sposób otrzymywania stabilizowanego roztworu substancji czynnych, kompozycja farmaceutyczna na bazie stabilizowanego roztworu substancji czynnych (dwa warianty) |
| CN107106594A (zh) * | 2014-12-26 | 2017-08-29 | 生化学工业株式会社 | 改善眼的自觉症状的制剂和方法 |
| WO2020022791A1 (ko) | 2018-07-25 | 2020-01-30 | (주)알테오젠 | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| CN112203642B (zh) | 2019-03-25 | 2025-03-07 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| CN121472194A (zh) | 2020-01-23 | 2026-02-06 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| JP7622088B2 (ja) | 2020-08-07 | 2025-01-27 | アルテオジェン・インコーポレイテッド | 組換えヒアルロニダーゼの生産方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635489B2 (en) * | 2001-05-18 | 2009-12-22 | Leneau Holdings, Llc | Ingestion of hyaluronic acid for improved joint health |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) * | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
-
2007
- 2007-11-23 IT IT002225A patent/ITMI20072225A1/it unknown
-
2008
- 2008-11-07 TW TW097142981A patent/TWI448292B/zh not_active IP Right Cessation
- 2008-11-10 PT PT08853047T patent/PT2222275E/pt unknown
- 2008-11-10 CA CA2706398A patent/CA2706398C/en not_active Expired - Fee Related
- 2008-11-10 RS RS20110524A patent/RS52045B/sr unknown
- 2008-11-10 CN CN2008801169202A patent/CN101868225B/zh not_active Expired - Fee Related
- 2008-11-10 PL PL08853047T patent/PL2222275T3/pl unknown
- 2008-11-10 EP EP08853047A patent/EP2222275B1/en active Active
- 2008-11-10 AP AP2010005265A patent/AP2628A/xx active
- 2008-11-10 UA UAA201006127A patent/UA97867C2/ru unknown
- 2008-11-10 HR HR20110904T patent/HRP20110904T1/hr unknown
- 2008-11-10 DK DK08853047.2T patent/DK2222275T3/da active
- 2008-11-10 SI SI200830475T patent/SI2222275T1/sl unknown
- 2008-11-10 US US12/743,891 patent/US9101627B2/en not_active Expired - Fee Related
- 2008-11-10 BR BRPI0820402-0A patent/BRPI0820402A2/pt not_active IP Right Cessation
- 2008-11-10 KR KR1020107011164A patent/KR101585868B1/ko not_active Expired - Fee Related
- 2008-11-10 MY MYPI2010002358A patent/MY148685A/en unknown
- 2008-11-10 GE GEAP200811807A patent/GEP20125602B/en unknown
- 2008-11-10 MX MX2010005484A patent/MX2010005484A/es active IP Right Grant
- 2008-11-10 ES ES08853047T patent/ES2374861T3/es active Active
- 2008-11-10 NZ NZ585514A patent/NZ585514A/en not_active IP Right Cessation
- 2008-11-10 AU AU2008328311A patent/AU2008328311B2/en not_active Ceased
- 2008-11-10 JP JP2010534395A patent/JP5383695B2/ja not_active Expired - Fee Related
- 2008-11-10 AT AT08853047T patent/ATE529096T1/de active
- 2008-11-10 EA EA201000678A patent/EA017626B1/ru not_active IP Right Cessation
- 2008-11-10 WO PCT/EP2008/009451 patent/WO2009065507A2/en not_active Ceased
- 2008-11-19 PE PE2008001955A patent/PE20091422A1/es not_active Application Discontinuation
- 2008-11-21 AR ARP080105077A patent/AR069407A1/es unknown
- 2008-11-21 PA PA20088804801A patent/PA8804801A1/es unknown
- 2008-11-21 CL CL2008003475A patent/CL2008003475A1/es unknown
-
2010
- 2010-05-05 EC EC2010010153A patent/ECSP10010153A/es unknown
- 2010-05-06 CO CO10054082A patent/CO6270301A2/es active IP Right Grant
- 2010-05-14 TN TN2010000215A patent/TN2010000215A1/fr unknown
- 2010-05-19 NI NI201000087A patent/NI201000087A/es unknown
- 2010-05-20 IL IL205860A patent/IL205860A/en not_active IP Right Cessation
- 2010-05-20 HN HN2010001037A patent/HN2010001037A/es unknown
- 2010-05-20 ZA ZA2010/03586A patent/ZA201003586B/en unknown
- 2010-05-21 CR CR11457A patent/CR11457A/es unknown
- 2010-06-15 MA MA32913A patent/MA31913B1/fr unknown
-
2011
- 2011-11-30 CY CY20111101177T patent/CY1112134T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091262A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
| MX369818B (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| CY1116892T1 (el) | Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| PE20130496A1 (es) | Tratamiento de artritis por lupus usando laquinimod | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| EA201401351A1 (ru) | Производные бензимидазол-пролина | |
| GT201300236A (es) | Derivados de pirrolo (2,3-d) pirimidina como inhibidores de quinasa relacionados con tropomiosina | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| UA110310C2 (uk) | Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar) | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| MX2010001338A (es) | Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas. | |
| MX2015015051A (es) | Formulaciones alternativas para polipeptidos de fusion tnfr:fc. | |
| JO3229B1 (ar) | العمل على استقرار الهرمون المنبه للجريب | |
| EA201490222A1 (ru) | Комбинированные составы на основе дарунавира | |
| CR20140007A (es) | N-(6-((2r, 3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina | |
| CL2011002213A1 (es) | Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras | |
| BR112014008312A2 (pt) | aditivos para cimento e métodos relacionados de uso | |
| ECSP13012453A (es) | 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3 | |
| CO6270301A2 (es) | Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos | |
| EA201300857A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| EA201170101A1 (ru) | Фармацевтические композиции роувастатина кальция | |
| EA201990723A1 (ru) | Кристаллические формы |